Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

I like it. I’m expecting 2024 calendar year top line to be about $145M, excluding any new major launches in back half, so primarily Prasco, organic + pricing. Selling into high growth phases is where Nasrat should be setting company up for. New storage + mfg space will set this up nicely from asset utilization perspective.

Higher legal fees would be adjusted out of EBITDA reporting if they had a decent IR staff since it’s not part of normal operations.

Not sure how much anticipated small drugs would bring in, but antimetabolite is another on shortage list…